TY - JOUR
T1 - Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)
AU - Di Giambenedetto, Simona
AU - Fabbiani, Massimiliano
AU - Quiros-Roldan, E.
AU - Latini, A
AU - D'Ettorre, G
AU - Antinori, A
AU - Castagna, A
AU - Orofino, Giancarlo
AU - Francisci, Daniela
AU - Chinello, P
AU - Madeddu, G
AU - Grima, Pierfrancesco
AU - Rusconi, Stefano
AU - Di Pietro, Massimo
AU - Mondi, A
AU - Ciccarelli, N
AU - Borghetti, Alberto
AU - Focà, Emanuele
AU - Colafigli, M
AU - De Luca, A
AU - Cauda, Roberto
AU - Atlas-M Study Group
N1 - Lazzarin, A; Bigoloni, A; Carini, E; Nozza, S; Spagnuolo, V in appendice
PY - 2017
Y1 - 2017
N2 - Background: Combination ART (cART)-related toxicities and costs have prompted the need for treatment simplification. The ATLAS-M trial explored 48 week non-inferior efficacy of simplification to atazanavir/ritonavir + lamivudine versus maintaining three-drug atazanavir/ritonavir-based cART in virologically suppressed patients. Methods: We performed an open-label, multicentre, randomized, non-inferiority study, enrolling HIV-infected adults on atazanavir/ritonavir+two NRTIs, with stable HIV-RNA 200 cells/mm3. Main exclusion criteria were hepatitis B virus coinfection, past virological failure on or resistance to study drugs, recent AIDS and pregnancy. Patients were randomly assigned 1:1 to either switch to 300mg of atazanavir/ 100mg of ritonavir once daily and 300mg of lamivudine once daily (atazanavir/ritonavir+lamivudine arm) or to continue the previous regimen (atazanavir/ritonavir+two NRTIs arm). The primary study outcome was the maintenance of HIV-RNA
AB - Background: Combination ART (cART)-related toxicities and costs have prompted the need for treatment simplification. The ATLAS-M trial explored 48 week non-inferior efficacy of simplification to atazanavir/ritonavir + lamivudine versus maintaining three-drug atazanavir/ritonavir-based cART in virologically suppressed patients. Methods: We performed an open-label, multicentre, randomized, non-inferiority study, enrolling HIV-infected adults on atazanavir/ritonavir+two NRTIs, with stable HIV-RNA 200 cells/mm3. Main exclusion criteria were hepatitis B virus coinfection, past virological failure on or resistance to study drugs, recent AIDS and pregnancy. Patients were randomly assigned 1:1 to either switch to 300mg of atazanavir/ 100mg of ritonavir once daily and 300mg of lamivudine once daily (atazanavir/ritonavir+lamivudine arm) or to continue the previous regimen (atazanavir/ritonavir+two NRTIs arm). The primary study outcome was the maintenance of HIV-RNA
U2 - 10.1093/jac/dkw557
DO - 10.1093/jac/dkw557
M3 - Article
VL - 72
SP - 1163
EP - 1171
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
SN - 0305-7453
IS - 4
ER -